At the time of writing there are some new lipid-lowering drugs on the market, but attempts to influence atherosclerosis by new mechanisms have unfortunately generally been unsuccessful so far. This article briefly reviews selected developments that may be of interest to the non-specialist practitioner.
These guidelines for prophylactic anticoagulation reflect current best practice. However, every patient should still be assessed on merit, with individualisation of therapy where indicated. Drug recommendations are based on Medicines Control Council registration at the time of publication, unless otherwise indicated. 1. Medical patients
Overactive bladder (OAB) is a medical syndrome defined by symptoms of urgency, with or without urge urinary incontinence (any involuntary loss of urine), usually with frequency and nocturia. Although anticholinergic agents have been the first-line treatment for OAB for many years, the efficacious pharmacologic management of this condition has been compromised by concerns regarding tolerability. […]
Introduction Stem cells are key players in the development and maintenance of specific mammalian tissues, and their presence has been long established in blood, skin and intestine. A general definition of stem cell is “a cell that is capable of both self renewal and differentiation”. Stem cells are considered multipotent; since they can produces mature […]
Fasting is an effective and safe method of detoxifying the body… it helps the body heal itself and stay well. Fasting can help reverse the aging process, and if we use it correctly we will live longer, happier lives. – James Balch, MD, Author, Prescription for Natural HealingAccepted as a classic cure for many medical […]
Angiogenesis is the growth of new blood vessels and is a key process which occurs during pathological disease progression. Excessive and damaging angiogenesis occurs in diseases such as cancer, diabetic retinopathies, age-related macular degeneration and atherosclerosis. In other diseases such as stroke and myocardial infarction, insufficient or improper angiogenesis results in tissue loss and ultimately […]
Introduction In the 1970s and 1980s, clinical bone marrow transplantation (BMT) required HLA matching between the donor and recipient to be successful. Although earlier BMT procedures occurred between siblings, current molecular techniques have enabled the precise characterization of major histocompatibility class and class II (MHC) genes, allowing the possibility of matching unrelated individuals. The first […]